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Summary
Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, 
paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and 
ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high 
risk of decompensation while approval of these regimens was pending in Italy.
Methods In this prospective observational study, we collected data from a compassionate use nationwide programme 
from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of 
decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once 
daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients 
with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir 
(25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based 
ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment 
(SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify 
baseline characteristics associated with SVR12. Adverse events were recorded throughout the study.
Findings 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without 
dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin 
concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83–12·3]; p=0·001). 
166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment 
because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) patients.
Interpretation Our findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or 
without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decompensation 
in a real-life setting are similar to those reported in clinical trials. The concordance with clinical trials provides reassurance 
that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practice.
Funding Dipartimento Biomedico di Medicina Interna e Specialistica dell’Universita di Palermo.
Introduction
European guidelines on the treatment of chronic 
hepatitis C virus (HCV) infection regard patients with 
cirrhosis as a high-priority population for treatment.1 In 
Europe, the all-oral, three direct-acting antiviral (DAA) 
regimen of ombitasvir, paritaprevir, and the pharma-
cokinetic enhancer ritonavir, with dasabuvir, with or 
without ribavirin is approved for the treatment of HCV 
genotype 1 infection, whereas the two DAA regimen of 
ombitasvir, paritaprevir, and ritonavir, plus ribavirin is 
approved for the treatment of HCV genotype 4 infection.2,3
In previously untreated or treated patients with 
compensated cirrhosis, 114 (94%) of 121 patients with 
genotype 1a infection had a sustained virological response 
at week 12 after the end of treatment (SVR12) with 
ombitasvir, paritaprevir, and ritonavir, with dasabuvir plus 
ribavirin for 24 weeks, and 60 (100%) of 60 patients with 
genotype 1b infection who were given a 12 week regimen 
of ombitasvir, paritaprevir, and ritonavir, with dasabuvir, 
without ribavirin achieved SVR12.4,5 In previously un-
treated or treated patients with genotype 4 infection and 
compensated cirrhosis, 60 (98%) of 61 patients who had 
16 weeks of treatment and 57 (97%) of 59 patients and 30 
(97%) of 31 patients, who had 12 weeks of treatment with 
the all-oral two-DAA regimen of ombitasvir, paritaprevir, 
and ritonavir, plus ribavirin achieved SVR12.6,7 The safety 
profiles of the ombitasvir, paritaprevir, and ritonavir, plus 
ribavirin regimens with or without dasabuvir in patients 
with compensated cirrhosis were similar to those in 
patients without cirrhosis.4–13
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Compassionate-use programmes for DAAs can provide 
access to drugs that have yet to be approved for high-priority 
patients with advanced, compensated cirrhosis who are at 
high risk of decompensation across a short timespan. 
Furthermore, these programmes provide additional early 
data on the effectiveness and safety of DAA regimens in 
general clinical practice and early experience of using new 
treatment regimens. With the support of the Italian 
Medicines Agency (Agenzia Italiana del Farmaco; AIFA), 
we did the AIFA-Based Associazione Italiana per lo Studio 
del Fegato (AISF) Compassionate Use Study (ABACUS) to 
provide access to ombitasvir, paritaprevir, and ritonavir, 
with dasabuvir, plus ribavirin for high-priority patients 
with genotype 1 HCV infection and ombitasvir, 
paritaprevir, and ritonavir, plus ribavirin for high-priority 
patients with genotype 4 infection while approval of these 
regimens was pending in Italy. We report the efficacy and 
safety of ombitasvir, paritaprevir, and ritonavir, with or 
without dasabuvir, plus ribavirin in patients with cirrhosis 
who completed or prematurely discontinued treatment.
Methods
Study design
ABACUS was a prospective, longitudinal, observational 
study. ABACUS was not a clinical trial, but a com-
passionate use programme, so there was no planned 
number of patients or sites. The compassionate use 
programme was initiated by AbbVie (Campoverde, Italy) 
on March 17, 2014. Recruitment was stopped on 
May 28, 2015, when ombitasvir, paritaprevir, and 
ritonavir, with or without dasabuvir, plus ribavirin 
received marketing approval by AIFA. Patients were 
recruited at 176 sites in Italy via a network established by 
AISF and AIFA. The data analysis cutoff was Feb 1, 2016. 
Patients were treated according to the European 
guidelines that were in use at the time of the study.1 
Briefly, patients with HCV genotype 1 infection who had 
cirrhosis were given coformulated ombitasvir (25 mg), 
paritaprevir (150 mg), and ritonavir (100 mg) once daily 
and dasabuvir (250 mg) twice daily for 12 weeks (patients 
with genotype 1b HCV infection) or 24 weeks (patients 
with genotype 1a HCV infection). Patients with geno-
type 4 infection who had cirrhosis were given 
coformulated ombitasvir (25 mg), paritaprevir (150 mg), 
and ritonavir (100 mg) for 24 weeks (appendix p 4). 
Ombitasvir, paritaprevir, ritonavir, and dasabuvir were 
provided by AbbVie. All patients were given weight-based 
doses of ribavirin (1000 mg for patients <75 kg, or 
1200 mg for patients ≥75 kg) as recommended by the 
drug label.14 Blood transfusions and use of erythropoietin 
were permitted if deemed medically necessary.
The study was done in accordance with the 
International Conference on Harmonisation guidelines, 
applicable regulations at each study site, and the 
principles of the Declaration of Helsinki. Local ethics 
approval was obtained at each site.
Patients
The ABACUS compassionate-use programme provided 
treatment access for patients with HCV genotype 1 or 4 
infection who had compensated cirrhosis and were 
at high risk of decompensation. High risk of de-
compensation was defined as clinical features suggestive 
of rapidly progressive fibrosis or impending de-
compensation (eg, a rapid decline in platelets, albumin 
concentration, or both) with previous signs or history of 
Research in context
Evidence before this study
We searched PubMed with search terms “ombitasvir”, 
“paritaprevir”, “dasabuvir”, “genotype 1”, “genotype 4”, and 
“cirrhosis” for trials of the all-oral three direct-acting antiviral 
(DAA) regimen of ombitasvir, paritaprevir, and ritonavir, with 
dasabuvir, with or without ribavirin in patients with hepatitis C 
virus (HCV) genotype 1 infection and the all-oral two-DAA 
regimen of ombitasvir, paritaprevir, and ritonavir, plus ribavirin 
in patients with HCV genotype 4 infection, published between 
Jan 1, 2014, and Dec 31, 2016. Only trials that included patients 
with compensated cirrhosis were selected. Three randomised, 
open-label trials and one single-arm, open-label trial were 
identified that met the criteria. In treatment-naive or 
treatment-experienced patients with compensated cirrhosis, 
treatment with ombitasvir, paritaprevir, and ritonavir, plus 
dasabuvir resulted in sustained virological response at week 12 
after the end of treatment (SVR12) in 94% of patients with HCV 
genotype 1a infection who were given a 24 week regimen with 
ribavirin and 100% of patients with HCV genotype 1b infection 
who were given a 12 week regimen without ribavirin. 
In treatment-naive or treatment-experienced patients with HCV 
genotype 4 infection and compensated cirrhosis, the all-oral 
two-DAA regimen of ombitasvir, paritaprevir, and ritonavir, plus 
ribavirin resulted in 100% of patients achieving SVR12 after 
16 weeks of treatment and 97% of patients achieving SVR12 
after 12 weeks of treatment.
Added value of this study
This compassionate-use programme of ombitasvir, paritaprevir, 
and ritonavir, with or without dasabuvir, plus ribavirin for 
patients with HCV genotype 1 infection and ombitasvir, 
paritaprevir, and ritonavir, plus ribavirin for patients with HCV 
genotype 4 infection provides valuable data on the effectiveness 
and safety of these DAA regimens in general clinical practice.
Implications of all the available evidence
Our findings suggest that the safety and effectiveness of 
ombitasvir, paritaprevir, and ritonavir, with or without 
dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 
infection and cirrhosis at high risk of decompensation in a 
real-world setting are similar to those reported in clinical trials.
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decompensation, or with rapid progression from 
histologically or clinically proven chronic HCV infection 
without cirrhosis to clinically diagnosed cirrhosis. All 
patients had Child-Pugh class A cirrhosis at the time of 
enrolment, but those with a history of decompensation 
were not excluded, and a change in Child-Pugh class 
could occur between enrolment and start of treatment. 
Diagnosis of cirrhosis at baseline was made by meeting 
at least one of the following criteria: histology from a 
liver biopsy, a FibroScan (Echosens, Paris, France) result 
of more than 14·6 kPa, a platelet count of less than 
100 000 cells per µL, or the presence of oesophageal 
varices. Patients could be treatment naive (defined as 
never having had HCV treatment), or treatment 
experienced (defined as having previous treatment with 
interferon-based therapy, with or without ribavirin, and 
being a non-responder or a relapser, or interferon-
intolerant).
All patients in the study provided written informed 
consent before any study-specific procedures were 
carried out.
Efficacy and safety assessments
Efficacy and safety assessments were at the discretion of 
the investigators because this was a compassionate use 
programme and not a clinical trial. HCV RNA testing 
was done at the local laboratory at each site. However, 
investigators were requested to do laboratory assess-
ments, including international normalised ratio (INR), 
albumin concentration, bilirubin concentration, alanine 
amino transferase (ALT) concentration, and haemoglobin 
concentration, at baseline, at treatment weeks 2 and 4, 
every 4 weeks during treatment thereafter, and at week 12 
after treatment. We assessed HCV RNA concentration at 
baseline, week 4 of treatment, end of treatment, and 
week 12 after treatment. We recorded data on adverse 
events throughout the study. Patient visits and follow-up, 
as well as laboratory testing, were done according to the 
sites’ local standards. Laboratory and safety data were 
reported on an ongoing basis on a spreadsheet to the 
principal investigator. All clinicians were invited to 
contribute to data collection, but not all clinicians 
contributed.
Outcomes
The primary efficacy endpoint was the percentage of 
patients achieving an HCV RNA concentration 
of less than 25 IU/mL 12 weeks after the end of therapy—
ie, SVR12—by intention to treat. Secondary endpoints 
were the percentage of patients with virological 
breakthrough during treatment or relapse after treat-
ment; effect of antiviral therapy on markers of liver 
function, such as INR, albumin concentration, and 
bilirubin concentration; safety events consistent with 
hepatic decompensation; and deaths during the study. 
We defined virological breakthrough during treatment 
as a confirmed HCV RNA concentration of 25 IU/mL or 
higher after achieving an HCV RNA concentration of 
lower than 25 IU/mL. We defined virological relapse as a 
confirmed HCV RNA concentration of 25 IU/mL or 
higher between the end of treatment and 12 weeks after 
the last dose of study drug in patients who had an HCV 
RNA concentration of lower than 25 IU/mL at the final 
visit during the treatment period.
Statistical analysis
We presented categorical variables as percentages, and 
continuous variables as mean (SD). We compared 
patients who achieved SVR12 with those who did not, 
and those who had a serious adverse event (including 
death, liver decompensation, infection, haemoglobin 
concentration <8 g/dL, or bilirubin concentration 
>10 g/dL) with those who did not using Pearson’s χ² test 
for categorical variables and Student’s t test for 
continuous data. We used univariate and multivariate 
logistic regression models to assess baseline charac-
teristics independently associated with SVR12 or serious 
adverse events. We modelled SVR12 and serious adverse 
events as the dependent variables. We regarded baseline 
characteristics associated with SVR12 or serious adverse 
events in univariate analyses (p≤0·1) as independent 
variables in the multivariate logistic regression models. 
We tested changes in biochemical parameters over time 
by means of a paired two-sample t test for comparisons 
that involved only two timepoints and by a linear 
mixed-effect regression model over time (with an 
intercept random effect for each patient) for comparisons 
that involved more than two timepoints. All analyses 
were done using IBM SPSS (version 18). We did efficacy 
analyses for patients with cirrhosis in the intention-to-treat 
(ITT) population (defined as all enrolled patients who 
were given at least one dose of study drug), and the 
per-protocol population (defined as all enrolled patients 
who completed treatment or discontinued treatment due 
to virological breakthrough).
Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Patients were enrolled in the study between March 17, 2014, 
and May 28, 2015. 934 patients with cirrhosis were given 
ombitasvir, paritaprevir, and ritonavir, with or without 
dasabuvir, plus ribavirin. 762 patients were included in the 
ITT population, 728 were included in the per-protocol 
population, and 734 were included in the safety population 
(figure; appendix p 5). Of the 172 patients who were not 
included in the ITT analysis, 128 were still on treatment or 
in the follow-up period before the week 12 follow-up visit at 
the time of the analysis, and clinicians chose not to provide 
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data for analysis and dissemination for the remaining 
44 patients. Baseline characteristics of patients with 
cirrhosis included in the study compared with those not 
included in the analysis were not substantially different. 
No patients were lost to follow-up. Baseline demographics 
and disease characteristics are presented in table 1. 
Previous decompensation was recorded in seven (18%) of 
39 patients with Child-Pugh class B cirrhosis. The mean 
age of patients with Child-Pugh class B cirrhosis was 
62·8 years (SD 9·4) and 24 (62%) patients were men. 
Patients with Child-Pugh class B cirrhosis at baseline were 
treated at the discretion of the site investigator. All patients 
with Child-Pugh A were treated. All 39 patients with Child-
Pugh class B cirrhosis were included in the ITT population, 
and 33 of these patients were included in the per-protocol 
population.
728 (96%) of 762 patients in the ITT population who 
were given ombitasvir, paritaprevir, and ritonavir, with or 
without dasabuvir, plus ribavirin therapy for 12 or 
24 weeks achieved SVR12 (table 2). The proportions of 
patients achieving SVR12 were similar in centres 
treating fewer than ten patients compared with centres 
treating ten or more patients (data not shown). SVR12 
rates in treatment history and baseline HCV RNA 
concentration subgroups did not differ from the overall 
proportion of patients achieving SVR12 (table 2). The 
proportion of patients achieving SVR12 did not differ 
substantially between treatment-naive and treatment-
experienced patients in HCV genotype subgroups 
(appendix p 6). There were significant differences in the 
proportion of patients achieving SVR12 by HCV 
genotype 1 subtype in the per-protocol population 
(genotype 1a 137 [95%] of 144 patients vs genotype 1b 
545 [98%] of 554 patients; p=0·02). There was no 
significant difference in the ITT population (table 2). 
The proportion of patients achieving SVR12 did not 
differ substantially by age, sex, or body-mass index 
(appendix p 7), renal function (appendix p 8), or by 
baseline FibroScan result (appendix p 9) in the ITT 
population. Analyses of SVR by age, sex, body-mass 
index, renal function, and baseline FibroScan score were 
not done in the per-protocol population. Fewer patients 
with Child-Pugh class B cirrhosis achieved SVR12 than 
patients with Child-Pugh A cirrhosis (p<0·0001; 
appendix p 10); there was no significant difference in 
SVR rate by MELD score. The proportion of patients 
achieving SVR12 was lower in patients with markers of 
more severe liver disease (p=0·01 for platelet count 
<100 000 cells per μL; p=0·01 for albumin <3·5 g/dL; 
and p=0·001 for bilirubin ≥2 mg/dL; appendix pp 10–11) 
by ITT. The proportion of patients achieving SVR12 who 
had HCV RNA concentrations of 25 IU/mL or lower at 
week 4 was significantly higher than those with HCV 
RNA concentrations higher than 25 IU/mL at week 4 
(p=0·002; appendix p 12). This was predominantly 
driven by the subgroup of patients with HCV genotype 1b 
infection who were given ombitasvir, paritaprevir, 
ritonavir, with dasabuvir plus ribavirin for 12 weeks. 
Ribavirin dose had no effect on the proportion of patients 
achieving SVR12 (appendix p 13).
In the per-protocol population, a lower proportion of 
patients achieving SVR12 was observed in patients 
with bilirubin concentration of 2 mg/dL or higher 
(p=0·003; appendix p 11), but no significant differences 
in SVR12 were recorded by presence of varices 
(appendix p 10) or other markers of severe liver disease 
(appendix p 11).
In the multivariate logistic regression analysis, the only 
factor with a significant association with SVR12 in the 
ITT population was a baseline bilirubin concentration of 
less than 2 mg/dL (odds ratio [OR] 4·76 [95% CI 
1·83–12·3]; p=0·001). In the per-protocol population, 
baseline factors associated with achieving SVR12 were 
genotype 1b infection (OR 2·97 [95% CI 1·08–8·22]; 
p=0·03) and bilirubin concentration of less than 2 mg/dL 
(4·88 [1·62–14·6]; p=0·005). In patients with HCV 
genotype 1b infection, baseline bilirubin concentration of 
lower than 2 mg/dL was independently associated with 
SVR12 (OR 5·09 [95% CI 1·74–14·8]; p=0·003). 
In patients with HCV genotype 1a infection, SVR12 
was marginally, though not significantly, associated with 
baseline bilirubin concentration of lower than 2 mg/dL 
(6·70 [0·95–46·9]; p=0·05) and baseline serum albumin 
concentration of 3·5 g/dL or higher (6·98 [1·21–40·2]; 
p=0·03). There were too few patients with genotype 4 
infection for subgroup analysis.
Figure: Study populations
*Data incomplete: treating physician chose not to provide data for analysis and 
dissemination. †Patients still on treatment, or in follow-up period before 
week 12 follow-up visit at the time of the analysis.
934 patients enrolled in the 
 compassionate use programme
728 included in per-protocol analysis
734 included in safety analysis




128 in treatment or post-treatment
follow-up†
28 safety data not available
34 excluded from per-protocol analysis
25 premature discontinuation of treatment 
due to adverse events
6 died
3 voluntary interruption of treatment
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In the ITT population, fewer patients achieved SVR12 
who had bilirubin concentrations of 2 mg/dL or higher 
and albumin concentrations of lower than 3·5 g/dL 
compared with those with other combinations of 
bilirubin and albumin values (appendix p 14). In the 
per-protocol population, the proportion of patients 
achieving SVR12 was lower in patients with HCV 
genotype 1a infection and bilirubin concentrations of 
2 mg/dL or higher compared with those with HCV 
genotype 1a infection and bilirubin concentrations lower 
than 2 mg/dL (appendix p 15).
Of patients who achieved SVR12, markers of liver 
function significantly improved by week 12 after 
treatment compared with baseline (appendix p 16). There 
was no significant difference in INR (p=0·34). Virological 
breakthrough occurred in four (1%) of 762 patients in the 
ITT population, whereas virological relapse occurred in 
14 (2%) of 762 patients. None of the patients who did not 
achieve SVR12 had liver decompensation up to 12 weeks 
after treatment. Most patients with Child-Pugh class B 
cirrhosis at baseline who achieved SVR12 had an 
improvement in Child-Pugh score, MELD score, or both 
(appendix p 17).
ALT concentrations rapidly decreased to normal levels 
with ombitasvir, paritaprevir, and ritonavir, with or 
without dasabuvir, plus ribavirin for 12 weeks, and 
remained at normal levels 12 weeks after treatment 
(appendix p 18). Bilirubin concentrations were raised at 
week 2 of treatment, but gradually decreased thereafter, 
and reached normal levels at week 12 after treatment 
(appendix p 18). Haemoglobin concentrations decreased 
with start of treatment, but plateaued at week 4, and 
returned to baseline values at week 12 after treatment 
(appendix p 19). Similar results were obtained with 
ombitasvir, paritaprevir, and ritonavir, with or without 
dasabuvir, plus ribavirin for 24 weeks (appendix p 20). 
Estimated creatinine clearance decreased during 
treatment with ombitasvir, paritaprevir, and ritonavir, 
with or without dasabuvir, plus ribavirin and remained 




Age (years) 59·2 (10·4)
Body-mass index
≥30 kg/m² 64 (8%)
<30 kg/m² 561 (74%)
Unknown 137 (18%)
Comorbidities
Lymphoproliferative disorder 20 (3%)
Cardiovascular disease 29 (4%)
Arterial hypertension 101 (13%)
Diabetes 95 (12%)
Thyroid dysfunction 25 (3%)
Psychiatric disorder 27 (4%)
Creatinine (mg/dL) 0·8 (0·5)
Creatinine clearance* (mL/min) 92·4 (16·9)





Alanine aminotransferase (IU/L) 89·0 (61·9)
Total bilirubin (mg/dL) 1·1 (0·6)
International normalised ratio 1·0 (0·2)
Albumin (g/dL) 3·9 (0·4)
Platelets (109 cells per L) 129 (74)
Child-Pugh class B 39 (5%)










Baseline HCV RNA concentration
>1 000 000 IU/mL 385 (51%)
<1 000 000 IU/mL 348 (46%)
Unknown 29 (4%)
Treatment naive 235 (31%)
History of previous liver decompensation 44 (6%)
Data are n (%) or mean (SD). ITT=intention to treat. HCV=hepatitis C virus. 
*Estimated glomerular filtration rate calculated by the Chronic Kidney Disease 
Epidemiology Collaboration equation. †Patients with unknown subtypes.
Table 1: Baseline characteristics
Proportion of patients 
who achieved SVR12
p value
All 728/762 (96%) ··
Treatment history
Treatment-naive 222/235 (94%) 0·33
Had pegylated interferon 
treatment
506/527 (96%) ··
Baseline HCV RNA concentration
<6 log IU/mL 336/348 (97%) 0·40
≥6 log IU/mL 367/385 (95%) ··
HCV genotype
1 712/745 (96%) ..
1a 143/154 (93%) 0·06 (vs 1b)
1b 554/575 (96%) ··
4 16/17 (94%) ··
Data are n/N (%). HCV=hepatitis C virus. SVR12=sustained virological response at 
week 12 after the end of treatment. ITT=intention to treat. 
Table 2: SVR12 in all patients with cirrhosis and by treatment history, 
baseline HCV RNA concentration, and HCV subtype (ITT population)
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(appendix p 22). There were no changes in blood glucose 
concentration during treatment and 12 weeks after 
treatment (appendix p 24).
166 (23%) of 734 patients had an adverse event. Rates 
of individual adverse events were low (table 3). Asthenia 
was the most commonly reported adverse event, 
occurring in 36 (5%) of patients. Severe anaemia 
(<8 g/dL haemoglobin) occurred in 18 (2%) patients. 
Blood transfusions were given to 14 (2%) patients and 
erythro poietin was given to 27 (4%) patients. 
Occurrences of hepatic decompensation (four [1%] of 
734 patients) and renal failure (two [<1%] of 734 patients) 
were low. 25 (3%) of 734 patients discontinued study 
drugs due to an adverse event. There were six deaths 
during the study (table 3). Multivariate logistic re-
gression analysis showed that bilirubin concentration 
of 2 g/dL or higher was significantly associated with 
serious adverse events (OR 3·23 [95% CI 1·37–7·69]; 
p=0·007). 
More adverse events took place in patients with 
Child-Pugh class B cirrhosis than those with Child-
Pugh A class cirrhosis (table 3), although the number 
of patients with Child-Pugh class B cirrhosis in this 
study was low.
Discussion
In this compassionate-use programme in patients with 
HCV genotype 1 or genotype 4 infection and cirrhosis, 
treatment with ombitasvir, paritaprevir, and ritonavir, 
with or without dasabuvir, plus ribavirin for 12 or 
24 weeks resulted in a high proportion of patients 
achieving SVR12, similar to the proportions reported in 
clinical trials of these regimens.4–7 To our knowledge, this 
is the largest real-life study of ombitasvir, paritaprevir, 
and ritonavir, with or without dasabuvir, plus ribavirin in 
patients with cirrhosis. The concordance between the 
proportion of patients achieving a SVR12 in this study 
and in clinical trials provides reassurance that the 
reported efficacy of this treatment in clinical trials will 
translate to its use in routine clinical practice. The high 
proportion of patients achieving SVR12 in this study is 
similar to those reported in other real-life studies of 
ombitasvir, paritaprevir, and ritonavir, with dasabuvir, 
with or without ribavirin in patients with HCV genotype 1 
infection and compensated cirrhosis.15–18
The strength of this study is that the study population 
was large and representative of patients with HCV 
genotype 1 infection with compensated cirrhosis in 
real-life clinical practice in Italy. This study has some 
limitations. Patients were not randomly assigned treat-
ment regimens or durations, and the choice of treatment, 
patient visits, and laboratory testing were at the 
investigators’ discretion. Moreover, the network of 
participating centres was established by AISF on the basis 
of the best expertise in HCV management, which could 
affect the external generalisability of our results. 
Furthermore, as efficacy and safety data were not provided 
by clinicians for all enrolled patients, it cannot be ruled 
out that the results of this study may slightly overestimate 
the efficacy and tolerability of ombitasvir, paritaprevir, 
and ritonavir, with or without dasabuvir, plus ribavirin.
At the time of this study, the label-recommended 
treatment of patients with genotype 1b infection and 
cirrhosis was a 12 week regimen of ombitasvir, 
paritaprevir, ritonavir, with dasabuvir plus ribavirin. The 
label-recommended treatment of this group of patients 
has been updated in the European Union (EU) to a 
12 week regimen of ombitasvir, paritaprevir, and ritonavir, 
with dasabuvir without ribavirin, based on the finding 
that 60 (100%) of 60 patients with genotype 1b infection 
and compensated cirrhosis achieved SVR12 with this 
regimen in the phase 3b TURQUOISE-III trial.4
The proportion of patients achieving SVR12 did not 
differ by ribavirin dose, but SVR12 was achieved in 
more patients with early virological response versus 
those without. This difference in the proportion of 
patients achieving a SVR12 by timing of virological 
response was predominantly driven by the subgroup of 
patients with HCV genotype 1b infection who were 
given ombitasvir, paritaprevir, and ritonavir, with 
dasabuvir plus ribavirin for 12 weeks, suggesting that 








Any adverse event 149 (21%) 17 (45%) 166 (23%)
Adverse event leading to 
discontinuation of study 
drugs
21 (3%) 4 (11%) 25 (3%)*
Death 4 (1%) 2 (5%) 6 (1%)†
Most common adverse events and adverse events of special interest
Asthenia 34 (5%) 2 (5%) 36 (5%)
Haemoglobin 
concentration <8 g/dL
17 (2%) 1 (3%) 18 (2%)
Infection 8 (1%) 3 (8%) 11 (1%)
Total bilirubin 
concentration >10 mg/dL
5 (1%) 3 (8%) 8 (1%)
Cardiovascular 7 (1%) 0 7 (1%)
Nausea 6 (1%) 0 6 (1%)
Hepatic 
decompensation‡
3 (<1%) 1 (3%) 4 (1%)
Renal failure 2 (<1%) 0 2 (<1%)
Data are n (%). Most common adverse events were those that occurred in 5% of 
patients or more in either group, while adverse events of special interest were 
anaemia (haemoglobin concentration <8 g/dL), hyperbilirubinaemia (total 
bilirubin >10 mg/dL), gastrointestinal adverse events, cardiovascular adverse 
events, renal adverse events, and those adverse events that were related to liver 
function or infections. *Included four cases of anaemia, three cases of infection, 
three cases of hyperbilirubinaemia, two cases of hepatic decompensation, and 
one case of hepatocellular carcinoma. †Two deaths were due to multiple organ 
failure (one as a result of cholecystitis leading to sepsis; one as a result of acute 
kidney injury following resection of hepatocellular carcinoma), one was due to 
hepatopulmonary syndrome as a result of pneumonia, one was due to a car 
accident, one was due to lymphoma, and one sudden death of unknown cause. 
‡Included variceal haemorrhage.
Table 3: Adverse events in all patients and by Child-Pugh score
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beneficial in patients with genotype 1b infection with 
late virological response. Despite these differences in 
the proportions of patients achieving a SVR12 between 
subgroups, the percentages were generally high (>90%). 
In patients who achieved a SVR12, markers of liver 
function, including albumin and bilirubin, significantly 
improved at week 12 after treatment compared with 
baseline, suggesting that SVR12 is associated with 
improvement of liver function.
In this compassionate-use programme, ombitasvir, 
paritaprevir, and ritonavir, with or without dasabuvir, 
plus ribavirin was generally well tolerated, with few 
patients who discontinued treatment due to adverse 
events. Few patients had severe anaemia, and blood 
transfusion and erythropoietin use was low. The rate of 
hepatic decompensation in this study was low (four [1%] 
of 734 patients), which is within the range for the 
previously reported annual risk of up to 6% for hepatic 
decompensation in patients with HCV infection and 
compensated cirrhosis.19,20
Increases in bilirubin concentrations reported in our 
study are consistent with those described in previous 
safety analyses of ombitasvir, paritaprevir, and ritonavir, 
with dasabuvir, with or without ribavirin.21 Increases in 
bilirubin concentrations reported in previous analyses 
were predominately indirect and related to the 
inhibition of the bilirubin transporters organic anion 
transporter polypeptide (OATP) 1B1 and 1B3 by 
paritaprevir and to ribavirin-induced haemolysis.21 
These increases in bilirubin concentration generally 
resolved and were not associated with increases in 
serum ALT.21 Increases in bilirubin concentrations seen 
in our study are therefore probably due to inhibition 
of the bilirubin transporters OATP1B1 and 1B3 by 
paritaprevir and ribavirin-induced haemolysis, rather 
than hepatotoxicity caused by ombitasvir, paritaprevir, 
and ritonavir, plus dasabuvir treatment.
Estimated creatinine clearance decreased slightly 
during treatment with ombitasvir, paritaprevir, and 
ritonavir, with or without dasabuvir, plus ribavirin. This 
effect is consistent with that shown in patients with 
normal renal function (estimated glomerular filtration 
rate [eGFR] >90 mL/min per 1·73 m²) in previous safety 
analyses of ombitasvir, paritaprevir, and ritonavir, with 
dasabuvir plus ribavirin in phase 2 and 3 clinical trials.22 
Conversely, mean eGFR increased in patients with 
baseline renal impairment.22 There were too few patients 
with baseline renal impairment to establish whether the 
same effect was present in our study.
More adverse events occurred in patients with 
Child-Pugh B cirrhosis compared with those with 
Child-Pugh A cirrhosis, although the number of patients 
with Child-Pugh B cirrhosis in this study was low. At the 
time of this compassionate-use programme, other HCV 
treatment regimens without protease inhibitors were 
not available. After enrolment in this compassionate 
use programme was closed, guidance for the use of 
ombitasvir, paritaprevir, and ritonavir, with or without 
dasabuvir, plus ribavirin in patients with Child-Pugh B was 
changed, and ombitasvir, paritaprevir, and ritonavir, with 
dasabuvir, and ombitasvir, paritaprevir, and ritonavir are 
not recommended in patients with Child-Pugh B cirrhosis 
in the EU at present.2,3 Our data confirm the European 
Medicines Agency’s recom mendation not to use these 
regimens in patients with Child-Pugh B cirrhosis.
In conclusion, data collected in this compassionate-
use programme suggest that the efficacy and safety 
profiles of ombitasvir, paritaprevir, and ritonavir, with or 
without dasabuvir, plus ribavirin in patients with HCV 
genotype 1 or 4 infection and advanced, compensated 
cirrhosis in a real-world setting are the same as those 
from clinical trials. Treatment of this population of 
patients is a high priority.
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